SCHEMBL5155307

SCHEMBL5155307

COC(=O)c1ccc(OC(F)(C(=O)Cc2ccc(NC(=O)Nc3ccccc3)cc2)N2CCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
EPHX2 P34913 5/20 0.45
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
MAPT P10636 4/20 0.45
KDM4E B2RXH2 3/20 0.45
P2RY1 P47900 1/20 0.44
FAAH O00519 2/20 0.43
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TNF P01375 1/20 0.43
NOD2 Q9HC29 1/20 0.43
NOD1 Q9Y239 1/20 0.43
HIF1A Q16665 2/20 0.43
MAPK1 P28482 2/20 0.43
HTT P42858 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152922 0.91 EPHX2 (0.50) NPC1RAB9AEPHX2MEN1KMT2A
SCHEMBL5149635 0.91 MAPT (0.56) NPC1RAB9AEPHX2MEN1KMT2A
SCHEMBL5151831 0.91 P2RY1 (0.47) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL5149725 0.90 RAB9A (0.52) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL5150238 0.90 P2RY1 (0.46) NPC1RAB9AEPHX2MEN1KMT2A
SCHEMBL5153046 0.90 MAPT (0.45) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL5155113 0.88 RAB9A (0.45) NPC1RAB9AEPHX2MEN1KMT2A
SCHEMBL5152494 0.85 RAB9A (0.52) NPC1RAB9AEPHX2MEN1KMT2A
SCHEMBL5153406 0.85 MAPT (0.47) NPC1RAB9AEPHX2MEN1KMT2A
SCHEMBL5149795 0.84 KDM4E (0.39) NPC1RAB9AEPHX2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 NPC1 3300/4885RAB9A 1984/4885EPHX2 3415/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 NPC1 2981/4885RAB9A 2225/4885EPHX2 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.